Clinical trial
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran…
NCT00262600 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00262600 |
|---|---|
| Title | Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate |
| Official title | Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Collaborators | Population Health Research Institute Uppsala University |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Stroke |
| Intervention type | Drug |
| Interventions | warfarin, Dabigatran dose 1, Dabigatran dose 2 |
| Enrollment | 18,113 |
| Start date | Dec 1, 2005 |
| Primary completion | Apr 1, 2009 |
| First posted | Dec 7, 2005 |
| Last update posted | Apr 17, 2019 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Finland and 32 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: